INO taking an overview of recommendation trends, INO has an average brokerage recommendation of 1.57. ABR value is precisely based on brokerage recommendations, where out of 7 brokerage recommendations 5 rate Inovio Pharmaceuticals, Inc. INO stock a Strong Buy, 0 rate the stocks of the company a Buy, 2 rate Hold, 0 rate Sell and 0 recommend a Strong Sell.
On 03-24-2020 (Tuesday), INO shares had a relatively better volume day versus average trading capacity of 11,550,869 shares, but with an 26.64M float and a 76.77% run over a month, it’s definitely worthy for investors
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) belongs to Healthcare sector and Biotechnology industry. The company’s Market capitalization is $1.11B with the total Outstanding Shares of 167.15M. INO‘s stock construct a change of 5.74% in a total of its share price and finished its trading at 7.00.
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, Inovio Pharmaceuticals, Inc. was unable to take a rebound, for now settling with 265.54% of loss for the given period.
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)
Having a glance at past record, we’re going to look at various forwards or backwards shifting developments regarding INO. The firm’s shares rose 7.99% in the past five business days. In the previous quarter, the stock rose 92.44% at some point. The output of the stock increased 166.94% within the six-month closing period, while general annual output gained 82.87%. The company’s performance is now positive at 100.61% from the beginning of the calendar year.
Earnings per Share Details of Inovio Pharmaceuticals, Inc.
Let’s take a quick analysis at INO’s past reported and future predictions of growth using the EPS Growth. EPS growth is a percentage change in standardized earnings per share over the trailing-twelve-month period to the current year-end.
The company posted a value of $-15.40% as earning-per-share over the last full year, while a chance, will post $1.30% for the coming year. In-depth, if we analyze for the long-term EPS Growth, the out-come was -14.60% for the past five years and the scenario is totally different as the prediction was 0.00% for the next five year.
P/S, P/E, P/C and P/B/ SMA50, SMA 200 of INO is described below
The price-to-sales is a valuation ratio that relates a company’s stock price to its revenues. The price-to-sales ratio is a symbol of the value placed on each dollar of a company’s sales or taxes. As of now, INO has a P/S, P/E and P/B values of 269.89, N/A and 220.67 respectively. P/E and P/B ratios both are used on a regular basis by the investor to measure the value of the company and to get the right amount of the share.
Its P/Cash valued at 12.36. The price-to-cash-flow ratio is a stock valuation indicator that measures the value of a stock’s price to its cash flow per share. Investors focus on the profitability proportions of the company that how the company performs at profitability side. Return on equity ratio or ROE is a significant indicator for prospective investors as they would like to see just how effectively a business is using their cash to produce net earnings.
Volatility Insights of INO
Watching some historical volatility numbers on shares of Inovio Pharmaceuticals, Inc. (INO) we can see that the 30 days volatility is presently 33.77%. The 7 days volatility is 18.02%. Following volatility data can help measure how much the stock price has fluctuated over the specified time period.
The company has a beta of Inovio Pharmaceuticals, Inc. 1.00 indicates that its price is correlated with the market. Less than 1.00 shows less volatility than the market. Beta greater than 1.00 indicates that the security’s price is theoretically more volatile than the market.
“INO” (Technical Considerations)
As a return on equity, Inovio Pharmaceuticals, Inc. (NASDAQ: INO) produces -283.10%. Because it would be easy and highly flexible, ROI measurement is among the most popular investment ratios. Executives could use it to evaluate the levels of performance on acquisitions of capital equipment whereas investors can determine that how the stock investment is better.
The ROI entry for INO’s scenario is at -137.90%. Another main metric of a profitability ratio is the return on assets ratio or ROA that analyses how effectively a business can handle its assets to generate earnings over duration of time. Inovio Pharmaceuticals, Inc. (INO) generated -73.30% ROA for the trading twelve-month.
What do you mean by simple moving average (SMA)?
Based on a recent bid, its distance from 20 days simple moving average is -1.38%, and it has a distance of 119.36% from the 200 days simple moving average.
The payout ratio shows the proportion of earnings paid out as dividends to shareholders, typically expressed as a percentage of the company’s earnings. It can also be expressed as dividends paid out as a proportion of cash flow. This is also known as the dividend payout ratio. INO’s payout ratio was N/A and Price to free cash flow remained $N/A.
Its quick ratio for most recent quarter was 2.90 along with current ratio for most recent quarter of 2.90. Total debt to equity ratio of the company for most recent quarter was 22.65 whereas long term debt to equity ratio for most recent quarter is 22.65.